https://www.fiercebiotech.com/biotech/nkartas-blood-cancer-car-stalls-again-falling-response-rate-forcing-it-out-race
Nkarta raised $230 million on the back of 4 out 6 complete responses in an early cohort. However, they only had 1 more complete response in the next 13 high dosed patients.
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial, page-39
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.001(2.78%) |
Mkt cap ! $15.41M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $1.658K | 89.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1300830 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 274059 | 3 |
View Market Depth
| Last trade - 10.36am 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.9¢ |
Change
0.001 ( 2.12 %) |
||||
| Open | High | Low | Volume | ||
| 1.9¢ | 1.9¢ | 1.9¢ | 50000 | ||
| Last updated 10.16am 31/05/2024 ? | |||||
| CHM (ASX) Chart |